Toray Industries, Inc. (東レ株式会社 Tōre Kabushiki-gaisha) is a multinational corporation headquartered in Japan that specializes in industrial products centered on technologies in organic synthetic chemistry, polymer chemistry, and biochemistry.

Cyrex Laboratories is a that specializes in providing clinical laboratory services for mucosal, cellular, and humoral immunology.

MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Herlev Hospital (former Danish: Amtssygehuset i Herlev) is a hospital in Herlev, Denmark, close to Copenhagen. The building is 120 metres (390 ft) tall and has 28 floors. It is famous for being Denmark's tallest building, and the eighth tallest hospital in the world. Its modern, functional architecture in bright concrete, glass and bronze-colored aluminum gives a unique impression.

Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA.

Incyte is a drug discovery and development company which hopes to build a proprietary product pipeline of novel small molecule drugs. Incyte's product pipeline is currently focused on oncology and inflammation and includes compounds in various stages of development. Through partnerships with [Novartis](/organization/novartis), [Eli Lilly](/organization/eli-lilly), and [Pfizer](/organization/pfizer), Incyte intends to promote the clinical development and global commercialization of several of their compounds.

Amager and Hvidovre Hospital is all about life. Life is about saving lives and giving life to the world. The quality of life for the patients and a good working environment for the employees. They Are ready with expertise and care around the clock. It is important for the patient to transition quickly from diagnosis to treatment and to return safely to everyday life. They act competently and carefully, even when life is at its worst. They are experts in folk diseases - the diseases that most people suffer from. In addition, they can provide highly specialized treatment to patients with rare diseases. They are proud of both. The work of hundreds of researchers every day is vital to the improvement and saving of lives. They develop and share new knowledge - it creates strong professional environments. The professionalism and development of all employees ensures good treatment of patients and an exciting working environment.

Cellestis Ltd. develops, manufactures and markets medical diagnostic products. It develops and markets QuantiFERON technology products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses of T cell lymphocytes using whole blood samples. Its product portfolio includes QuantiFERON-CMI kit, an in vitro laboratory test for the measurement of cell mediated immune responses in humans using whole blood, QuantiFERON-TB Gold, an in vitro diagnostic test for the detection of mycobacterium tuberculosis infection. The company was founded in 2000 and is headquartered in Chadstone, Australia.

B·R·A·H·M·S explores, develops and produces new diagnostic test procedures to improve the diagnosis, and thereby the treatment, of life-threatening illnesses. This takes place with over 400 employees, on the basis of their own patented biomarkers, and leads to medically and economically superior diagnostic insights for patients and medical professionals. B·R·A·H·M·S products reach customers in over 65 countries around the world and are leaders in their specialized markets.

Cambridge University Technical Services Ltd., part of University of Cambridge, is a British company located in Cambridge. The firm provides consulting services. It was founded in 2006.

Hadasit is the technology transfer company of Hadassah Medical Center in Jerusalem. They transform the cutting-edge research coming out of Hadassah into marketable medical technologies. They turn ground-breaking ideas into viable products and services that can change the world and better humanity. For more than a century, Hadassah has set the standard of excellence for medical care and research in Israel. Their doctors and scientists are on the frontlines, uniquely positioned to pinpoint ever-evolving medical needs. Their experience and ingenuity has yielded new ideas with huge potential in all areas of medicine, including therapeutics, diagnostic medical devices, and digital health. More than half of all hospital research in Israel is conducted at Hadassah. Hadasit is Hadassah’s vehicle for commercialization of the intellectual property and R&D capabilities developed there. Hadasit holds exclusive rights to every innovation and invention emerging from Hadassah and they are dedicated to bringing these life-saving technologies to the general public.

Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. These potential therapies could provide novel strategies for the treatment and management of a wide range of tumor types.

Immunosciences Lab is a clinical immunology, medical, and diagnostic laboratory.

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.